

Proteasome Inhibitors Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

<https://marketpublishers.com/r/P697B1C4B3C4EN.html>

Date: March 2025

Pages: 130

Price: US\$ 4,850.00 (Single User License)

ID: P697B1C4B3C4EN

Abstracts

The Global Proteasome Inhibitors Market was valued at USD 2.7 billion in 2024 and is projected to expand at a CAGR of 8.7% from 2025 to 2034. Proteasome inhibitors, a class of cytotoxic medications, block the chymotrypsin-like enzymatic activity of the proteasome, disrupting protein degradation within cells and exhibiting strong anticancer potential. Currently, these inhibitors are primarily used in oncology to treat conditions such as multiple myeloma and mantle cell lymphoma. Ongoing clinical trials aim to broaden the scope of their clinical applications. Pharmaceutical companies are increasing investments in research and development to introduce new proteasome inhibitors with higher efficacy, broader clinical indications, and improved compatibility for combination therapies. The growing focus on enhancing treatment outcomes and addressing drug resistance is driving innovation in this market.

The market is segmented by drug type into branded and generic categories. Branded proteasome inhibitors accounted for 64.8% of the total market share in 2024, driven by the rising adoption of targeted therapies to manage multiple myeloma. Increased incidence of multiple myeloma globally is boosting demand for branded medications with proven efficacy and superior patient outcomes. Branded therapies exhibit higher target affinity, enabling effective inhibition of proteasome activity and better disease control. The growing use of combination therapies, such as combining proteasome inhibitors with immunomodulatory agents and corticosteroids, is further accelerating segment growth.

By application, the proteasome inhibitors market is divided into multiple myeloma and mantle cell lymphoma. Multiple myeloma therapies accounted for 92.5% of the market share in 2024, primarily due to a rising number of newly diagnosed cases and increased awareness about early detection and treatment. The growing prevalence of multiple myeloma is prompting patients and healthcare providers to seek more targeted

treatment options, which include proteasome inhibitors. Increased access to innovative therapies and improved diagnostic technologies has significantly expanded the patient pool eligible for treatment with proteasome inhibitors.

The distribution channel segmentation includes hospital pharmacies, retail pharmacies, and e-commerce. Hospital pharmacies generated USD 1.9 billion in revenue in 2024, dominating the distribution landscape. Proteasome inhibitors are typically administered via subcutaneous or intravenous routes, requiring specialized care in hospital settings. Hospitals are well-equipped to manage complex therapies and monitor potential side effects, which encourages higher procurement of these medications from hospital pharmacies. Additionally, major insurance providers offer more favorable reimbursement rates for hospital-based purchases, further strengthening the dominance of this segment.

In North America, the US proteasome inhibitors market is expected to grow substantially, increasing from USD 1.1 billion in 2024 to USD 2.5 billion by 2034. High incidence rates of multiple myeloma, along with advancements in screening and diagnostic technologies, are driving market growth. The presence of leading biotechnology and pharmaceutical companies focused on developing novel proteasome inhibitors is contributing significantly to regional market expansion. As research efforts continue to unlock new therapeutic applications, the market is set to witness strong growth through the forecast period.

Contents

CHAPTER 1 METHODOLOGY AND SCOPE

- 1.1 Market scope and definitions
- 1.2 Research design
 - 1.2.1 Research approach
 - 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
 - 1.3.1 Base year calculation
 - 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
 - 1.5.1 Primary sources
 - 1.5.2 Data mining sources

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Industry 360° synopsis

CHAPTER 3 INDUSTRY INSIGHTS

- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
 - 3.2.1 Growth drivers
 - 3.2.1.1 Rising prevalence of multiple myeloma and related cancers
 - 3.2.1.2 Advancements in drug development and approvals
 - 3.2.1.3 Growing investments in oncology research
 - 3.2.1.4 Expansion in emerging markets
 - 3.2.2 Industry pitfalls and challenges
 - 3.2.2.1 High treatment costs
 - 3.2.2.2 Adverse side effects and drug resistance
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Gap analysis
- 3.6 Patent analysis
- 3.7 Pipeline analysis
- 3.8 Porter's analysis
- 3.9 PESTEL analysis

CHAPTER 4 COMPETITIVE LANDSCAPE, 2024

- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard

CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY DRUG TYPE, 2021 – 2034 (\$ MN)

- 5.1 Key trends
- 5.2 Branded
 - 5.2.1 Velcade (bortezomib)
 - 5.2.2 Kyprolis (carfilzomib)
 - 5.2.3 Ninlaro (Ixazomib)
- 5.3 Generic

CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2021 – 2034 (\$ MN)

- 6.1 Key trends
- 6.2 Multiple myeloma
- 6.3 Mantle cell lymphoma

CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY DISTRIBUTION CHANNEL, 2021 – 2034 (\$ MN)

- 7.1 Key trends
- 7.2 Hospital pharmacies
- 7.3 Retail pharmacies
- 7.4 E-commerce

CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2034 (\$ MN)

- 8.1 Key trends

8.2 North America

8.2.1 U.S.

8.2.2 Canada

8.3 Europe

8.3.1 Germany

8.3.2 UK

8.3.3 France

8.3.4 Spain

8.3.5 Italy

8.3.6 Netherlands

8.4 Asia Pacific

8.4.1 China

8.4.2 Japan

8.4.3 India

8.4.4 Australia

8.4.5 South Korea

8.5 Latin America

8.5.1 Brazil

8.5.2 Mexico

8.5.3 Argentina

8.6 Middle East and Africa

8.6.1 South Africa

8.6.2 Saudi Arabia

8.6.3 UAE

CHAPTER 9 COMPANY PROFILES

9.1 Amgen

9.2 Apotex

9.3 Aurobindo Pharma

9.4 Baxter International

9.5 Bristol Myer Squibb

9.6 Camber Pharmaceuticals

9.7 Dr. Reddy's Laboratories

9.8 Eugia US

9.9 Fresenius Kabi

9.10 Gland Pharma

9.11 Johnson & Johnson

9.12 QLi5 Therapeutics

9.13 Sagent Pharmaceuticals

9.14 Selleck Chemicals

9.15 Takeda Pharmaceutical Company

9.16 Zydus

I would like to order

Product name: Proteasome Inhibitors Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

Product link: <https://marketpublishers.com/r/P697B1C4B3C4EN.html>

Price: US\$ 4,850.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P697B1C4B3C4EN.html>